BARDA will procure Emergent BioSolutions’ AV7909 anthrax vaccine in Strategic National Stockpile

The US Biomedical Advanced Research and Development Authority (BARDA) will procure Emergent BioSolutions’ anthrax vaccine into the Strategic National Stockpile. The plan is to deliver the vaccine into the Strategic National Stockpile in the second half of 2019.

A pivotal test of malaria vaccine is set to begin. Can it live up to its promise?

Over the next four years, the experiences of these countries will help the WHO determine if RTS,S can be effectively used, and whether it will deliver the nearly 40 percent decrease in malaria infections seen in an earlier Phase 3 clinical trial.To see whether a new malaria vaccine, RTS, is effective, the World Health Organization (WHO) and partners have devised a limited rollout of the vaccine in Malawi followed by Ghana and Kenya.

Single dose of DPX-rPA, an enhanced-delivery anthrax vaccine formulation, protects against a lethal Bacillus anthracis spore inhalation challenge

The current study investigated the immunogenicity and protective response of rPA antigen formulated with the DPXTM no-release delivery platform (DPX-rPA). This unique formulation promotes a depot effect that attracts antigen-presenting cells to the vaccination site and elicits an immune response following single-dose delivery.